BioAtla, Inc.
BCAB$6M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO
Drugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BCAB News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
CAB-AXL-ADC
Undifferentiated Pleomorphic Sarcoma
BA3071
NSCLC
CAB-ROR2-ADC
Non Small Cell Lung Cancer
Ozuriftamab Vedotin
Head and Neck Cancer
PD-1 inhibitor
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAB-AXL-ADC | Phase 2 | Undifferentiated Pleomorphic Sarcoma | - | - |
BA3071 | Phase 2 | NSCLC | - | - |
CAB-ROR2-ADC | Phase 2 | Non Small Cell Lung Cancer | - | - |
Ozuriftamab Vedotin | Phase 2 | Head and Neck Cancer | - | - |
PD-1 inhibitor | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply